A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Johns Hopkins researchers have developed an AI-driven liquid biopsy that uses cell-free DNA fragmentation patterns to detect early liver fibrosis and cirrhosis, according to a study in Science Translational Medicine.
The new platform delivers twice the throughput in half the footprint of the previous generation, targeting large-scale genomic applications.
Ambry Genetics has completed its one millionth DNA/RNA genetic test, highlighting increased adoption of RNA-enhanced diagnostics for hereditary cancer and rare diseases, according to the company.
Read More
A bipartisan House bill would require Medicaid to cover whole genome and exome sequencing for children with suspected rare diseases, aiming to improve diagnostic access and reduce costs, according to lawmakers and recent pilot programs.
Read More
The BLOODPAC Consortium has released new analytical validation standards for liquid biopsy MRD tests, offering industry-wide protocols for tumor-informed ctDNA assay development, as detailed in JCO Precision Oncology.
Read More
Bridge Capture, a targeted NGS method, showed higher sensitivity for detecting rare ctDNA variants than two leading liquid biopsy assays, according to research in The Journal of Molecular Diagnostics.
Read More
Weill Cornell Medicine researchers report a whole-genome sequencing algorithm may identify more patients for PARP inhibitor cancer therapies than current commercial tests, according to a study in Communications Medicine.
Read More
New kit cuts sample-to-result time to 75 minutes while maintaining sensitivity for drug metabolism studies.
Read More
Researchers have developed a tool that measures gut-specific inflammation, potentially improving IBD diagnosis and monitoring.
Read More
University of Washington researchers find rapid test could improve treatment rates but may face implementation barriers due to reimbursement challenges.
Read More
The collaboration integrates AI-driven blood testing with a nationwide hepatology specialist network to reduce diagnostic delays.
Read More
Partnership with Certest Biotec adds respiratory and STI molecular diagnostic panels for European laboratories.
Read More
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read More
The version 2.0 systems feature increased throughput, expanded assay flexibility, and the ability to run up to six unique assays per run.
Read More
Hospital teams can trial the company’s BSI/AMR test and preview the LiDia-SEQ system ahead of commercial launch.
Read More
The precision medicine company now has 57 approvals in the US and 43 in Japan for its FoundationOne CDx and FoundationOne Liquid CDx tests.
Read More
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read More